NCCN Guidelines for Patients® | Multiple Myeloma

49 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 4 Treatment guide Active (symptomatic) multiple myeloma Myeloma therapy for previously treated multiple myeloma Preferred options Other options Useful for some patients • Repeat primary induction therapy (if relapse at >6 months) • Bendamustine/ bortezomib/ dexamethasone • Ixazomib/ dexamethasone • Bendamustine • Bortezomib/ lenalidomide/ dexamethasone • Bendamustine/ lenalidomide/ dexamethasone • Ixazomib/ pomalidomide/ dexamethasone • Dexamethasone/ cyclophosphamide/etoposide/ bortezomib • Carfilzomib (twice weekly)/ dexamethasone • Bortezomib/liposomal doxorubicin/ dexamethasone • Lenalidomide/ dexamethasone • Dexamethasone/thalidomide/ cisplatin/doxorubucin/ cyclophosphamide/etoposide ± bortezomib • Carfilzomib/ lenalidomide/ dexamethasone • Bortezomib/ cyclophosphamide/ dexamethasone • Panobinostat/ bortezomib/ dexamethasone • High-dose cyclophosphamide • Daratumumab/ bortezomib/ dexamethasone • Carfilzomib/ cyclophosphamide/ dexamethasone • Panobinostat/ Carfilzomib • Daratumumab/ lenalidomide/ dexamethasone • Carfilzomib(weekly)/ dexamethasone • Panobinostat/ lenalidomide/ dexamethasone • Elotuzumab/ lenalidomide/ dexamethasone • Cyclophosphamide/ lenalidomide/ dexamethasone • Pomalidomide/ cyclophosphamide/ dexamethasone • Ixazomib/lenalidomide/ dexamethasone • Bortezomib/ dexamethasone • Pomalidomide/ dexamethasone • Daratumumab • Pomalidomide/ bortezomib/ dexamethasone • Daratumumab/ pomalidomide/ dexamethasone • Pomalidomide/ carfilzomib/ dexamethasone • Elotuzumab/ bortezomib/ dexamethasone

RkJQdWJsaXNoZXIy MTE3MTE1